Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Relative Bioavailability of Basaglar (LY2963016) vs Lantus in Healthy Chinese Subjects
NCT03555305Phase 1Completed
- Sponsor
- Eli Lilly and Company
- Start
- Sep 2018
- Primary completion
- Nov 2019
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 1, randomised trial of insulin glargine in diabetes mellitus (DM) (2 arms), sponsored by Eli Lilly and Company. Primary endpoints: Maximum Serum Concentration and Area Under the Concentration Versus Time Curve. Started Sep 2018; status: completed.
02
Drugs
insulin glargine
03
Conditions
diabetes mellitus (DM)
Beyond the preview
Go deeper on NCT03555305.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03555305.